深夜在线观看免费高清在线影院av,最近最新中文字幕MV免费版,91香蕉视频好色先生TV下载,国产一二中文字幕91影院日韩欧美

Keryx Biopharmaceuticals  
專注于收購，開發(fā)和商業(yè)化的醫(yī)學(xué)治療腎臟疾病的重要醫(yī)藥產(chǎn)品。

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."